Cambridge Biotech Co-Founded by Alnylam Founder Files for NASDAQ IPO
A Cambridge-based biotech co-founded by Alnylam's CEO John Maraganore filed for an IPO with the SEC on September 25, 2026. The company focuses on RNA-targeted therapeutics, remains pre-revenue, and plans to list on NASDAQ. No underwriters were named in the initial filing.
51CFO view：CFOs of pre-commercial biotechs must master SEC-specific R&D accounting (ASC 730), build robust non-GAAP metrics (e.g., cash runway reporting), and structure MD&A disclosures that satisfy Item 10(e) without overstating clinical progress — all while maintaining SOX 404(a) readiness from Day 1 of filing.
A Cambridge-based biotech co-founded by Alnylam's CEO John Maraganore filed for an IPO with the SEC on September 25, 2026. The company focuses on RNA-targeted therapeutics, remains pre-revenue, and plans to list on NASDAQ. No underwriters were named in the initial filing.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →